SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Top Cited Papers
- 7 December 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 22 (1), 57-65
- https://doi.org/10.1038/s41577-021-00662-4
Abstract
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in fully vaccinated individuals are receiving intense scrutiny because of their importance in determining how long restrictions to control virus transmission will need to remain in place in highly vaccinated populations as well as in determining the need for additional vaccine doses or changes to the vaccine formulations and/or dosing intervals. Measurement of breakthrough infections is challenging outside of randomized, placebo-controlled, double-blind field trials. However, laboratory and observational studies are necessary to understand the impact of waning immunity, viral variants and other determinants of changing vaccine effectiveness against various levels of coronavirus disease 2019 (COVID-19) severity. Here, we describe the approaches being used to measure vaccine effectiveness and provide a synthesis of the burgeoning literature on the determinants of vaccine effectiveness and breakthrough rates. We argue that, rather than trying to tease apart the contributions of factors such as age, viral variants and time since vaccination, the rates of breakthrough infection are best seen as a consequence of the level of immunity at any moment in an individual, the variant to which that individual is exposed and the severity of disease being considered. We also address key open questions concerning the transition to endemicity, the potential need for altered vaccine formulations to track viral variants, the need to identify immune correlates of protection, and the public health challenges of using various tools to counter breakthrough infections, including boosters in an era of global vaccine shortages.Keywords
This publication has 135 references indexed in Scilit:
- Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort studyThe Lancet Infectious Diseases, 2014
- A Missing Dimension in Measures of Vaccination ImpactsPLoS Pathogens, 2014
- Estimating the Per-Exposure Effect of Infectious Disease InterventionsEpidemiology, 2014
- Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 YearsThe American Journal of Tropical Medicine and Hygiene, 2013
- Nomenclature for Immune Correlates of Protection After VaccinationClinical Infectious Diseases, 2012
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensThe New England Journal of Medicine, 2007
- Pandemic versus Epidemic Influenza Mortality: A Pattern of Changing Age DistributionThe Journal of Infectious Diseases, 1998
- Humoral Immunity Due to Long-Lived Plasma CellsImmunity, 1998